Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Non-Current Debt: 2021-2024

Historic Non-Current Debt for Legend Biotech (LEGN) over the last 4 years, with Dec 2024 value amounting to $301.2 million.

  • Legend Biotech's Non-Current Debt changed negligibly% to $2,000.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2,000.0 billion, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $2,000.0 billion for FY2024, which is negligibly% changed negligibly from last year.
  • As of FY2024, Legend Biotech's Non-Current Debt stood at $2,000.0 billion, which was down 0.00% from $2,000.0 billion recorded in FY2023.
  • Legend Biotech's Non-Current Debt's 5-year high stood at $2,000.0 billion during FY2022, with a 5-year trough of $2,000.0 billion in FY2022.
  • Moreover, its 3-year median value for Non-Current Debt was $281.3 million (2023), whereas its average is $281.2 million.
  • Data for Legend Biotech's Non-Current Debt shows a peak YoY spiked of 116.61% (in 2022) over the last 5 years.
  • Yearly analysis of 4 years shows Legend Biotech's Non-Current Debt stood at $120.5 million in 2021, then skyrocketed by 116.61% to $260.9 million in 2022, then increased by 7.82% to $281.3 million in 2023, then grew by 7.06% to $301.2 million in 2024.